Archive

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text css=".vc_custom_1747656706954{padding-bottom: 30px !important;}"] ELK-003 - an opthalmic solution for the treatment of corneal abrasions associated with epidermolysis bullosa [ninja_tables id="20545"] Investment summary Eliksa Therapeutics is developing ELK-003, a topical eye drop with the potential to both prevent and treat painful corneal...

This study endeavours to develop personalised therapies for individuals diagnosed with RDEB. ...

Nonsense Tx reading through disease causing nonsense codons...

siRNA-mediated allele-specific inhibition of mutant KRT5 and KRT14 transcripts carrying frequent dominant mutations in epidermolysis bullosa simplex (EBS)....

Development of a topical gel formulation of decorin to reduce fibrosis...

Development of IV-administered siRNAs targeting mutant KRT5 and KRT1 in EB Simplex...

Development of an oral formulation of the peptide angiotensin-(1-7) to reduce fibrosis...